Vinicius Cardoso Soares

Dr. Vinicius Cardoso Soares

Oswaldo Cruz Foundation (FIOCRUZ)
+1
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2020 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
Suelen Silva Gomes DiasSuelen Silva Gomes Dias
Suelen Silva Gomes Dias
Vinicius Cardoso SoaresVinicius Cardoso Soares
Vinicius Cardoso Soares
AFAndré Costa Ferreira
André Costa Ferreira
Carolina SacramentoCarolina Sacramento
Carolina Sacramento
NFNatalia Fintelman-Rodrigues
Natalia Fintelman-Rodrigues
PBPatricia Bozza
Patricia Bozza
Viruses are obligate intracellular parasites that make use of the host metabolic machineries to meet their biosynthetic needs. Thus, identifying the host pathways essential for the virus replication may lead to potential targets for therapeutic intervention. The mechanisms and pathways explored by SARS-CoV-2 to support its replication within host cells are not fully known. Lipid droplets (LD) are organelles with major functions in lipid metabolism, energy homeostasis and intracellular transport, and have multiple roles in infections and inflammation. Here we described that monocytes from COVID-19 patients have an increased LD accumulation compared to SARS-CoV-2 negative donors. In vitro, SARS-CoV-2 infection were seen to modulate pathways of lipid synthesis and uptake as monitored by testing for CD36, SREBP-1, PPARγ, and DGAT-1 expression in monocytes and triggered LD formation in different human cell lines. LDs were found in close apposition with SARS-CoV-2 proteins and double-stranded (ds)-RNA in infected Vero cells. Electron microscopy (EM) analysis of SARS-CoV-2 infected Vero cells show viral particles colocalizing with LDs, suggestive that LDs might serve as an assembly platform. Pharmacological modulation of LD formation by inhibition of DGAT-1 with A922500 significantly inhibited SARS-CoV-2 replication as well as reduced production of mediators pro-inflammatory response. Taken together, we demonstrate the essential role of lipid metabolic reprograming and LD formation in SARS-CoV-2 replication and pathogenesis, opening new opportunities for therapeutic strategies to COVID-19.

1 March 2021 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
AFAndré Costa Ferreira
André Costa Ferreira
Vinicius Cardoso SoaresVinicius Cardoso Soares
Vinicius Cardoso Soares
IAIsaclaudia G. de Azevedo-Quintanilha
Isaclaudia G. de Azevedo-Quintanilha
Suelen Silva Gomes DiasSuelen Silva Gomes Dias
Suelen Silva Gomes Dias
NFNatalia Fintelman-Rodrigues
Natalia Fintelman-Rodrigues
TSThiago Moreno Lopes e Souza
Thiago Moreno Lopes e Souza
Infection by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been associated with leukopenia and uncontrolled inflammatory response in critically ill patients. A better comprehension of SARS-CoV-2-induced monocyte death is essential for the identification of therapies capable to control the hyper-inflammation and reduce viral replication in patients with 2019 coronavirus disease (COVID-19). Here, we show that SARS-CoV-2 engages inflammasome and triggers pyroptosis in human monocytes, experimentally infected, and from patients under intensive care. Pyroptosis associated with caspase-1 activation, IL-1ß production, gasdermin D cleavage, and enhanced pro-inflammatory cytokine levels in human primary monocytes. At least in part, our results originally describe mechanisms by which monocytes, a central cellular component recruited from peripheral blood to respiratory tract, succumb to control severe COVID-19.

21 September 2020 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
NFNatalia Fintelman-Rodrigues
Natalia Fintelman-Rodrigues
CSCarolina Q. Sacramento
Carolina Q. Sacramento
CLCarlyle Lima
Carlyle Lima
FSFranklin Souza da Silva
Franklin Souza da Silva
AFAndré C. Ferreira
André C. Ferreira
TSThiago Moreno Lopes e Souza
Thiago Moreno Lopes e Souza
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is already responsible for far more deaths than previous pathogenic coronaviruses (CoVs) from 2002 and 2012. The identification of clinically approved drugs to be repurposed to combat 2019 CoV disease (COVID-19) would allow the rapid implementation of potentially life-saving procedures. The major protease (Mpro) of SARS-CoV-2 is considered a promising target, based on previous results from related CoVs with lopinavir (LPV), an HIV protease inhibitor.

21 April 2021 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
CSCarolina Q Sacramento
Carolina Q Sacramento
NFNatalia Fintelman-Rodrigues
Natalia Fintelman-Rodrigues
JTJairo R Temerozo
Jairo R Temerozo
ASAline de Paula Dias Da Silva
Aline de Paula Dias Da Silva
Suelen Silva Gomes DiasSuelen Silva Gomes Dias
Suelen Silva Gomes Dias
TSThiago Moreno Lopes e Souza
Thiago Moreno Lopes e Souza
Current approaches of drug repurposing against COVID-19 have not proven overwhelmingly successful and the SARS-CoV-2 pandemic continues to cause major global mortality. SARS-CoV-2 nsp12, its RNA polymerase, shares homology in the nucleotide uptake channel with the HCV orthologue enzyme NS5B. Besides, HCV enzyme NS5A has pleiotropic activities, such as RNA binding, that are shared with various SARS-CoV-2 proteins. Thus, anti-HCV NS5B and NS5A inhibitors, like sofosbuvir and daclatasvir, respectively, could be endowed with anti-SARS-CoV-2 activity. SARS-CoV-2-infected Vero cells, HuH-7 cells, Calu-3 cells, neural stem cells and monocytes were used to investigate the effects of daclatasvir and sofosbuvir. In silico and cell-free based assays were performed with SARS-CoV-2 RNA and nsp12 to better comprehend the mechanism of inhibition of the investigated compounds. A physiologically based pharmacokinetic model was generated to estimate daclatasvir’s dose and schedule to maximize the probability of success for COVID-19. Daclatasvir inhibited SARS-CoV-2 replication in Vero, HuH-7 and Calu-3 cells, with potencies of 0.8, 0.6 and 1.1 μM, respectively. Although less potent than daclatasvir, sofosbuvir alone and combined with daclatasvir inhibited replication in Calu-3 cells. Sofosbuvir and daclatasvir prevented virus-induced neuronal apoptosis and release of cytokine storm-related inflammatory mediators, respectively. Sofosbuvir inhibited RNA synthesis by chain termination and daclatasvir targeted the folding of secondary RNA structures in the SARS-CoV-2 genome. Concentrations required for partial daclatasvir in vitro activity are achieved in plasma at Cmax after administration of the approved dose to humans. Daclatasvir, alone or in combination with sofosbuvir, at higher doses than used against HCV, may be further fostered as an anti-COVID-19 therapy.

1 September 2022 in Blood Advances
Verified
Journal Article
Open access
PDF file
EHEugenio DAMACENO Hottz
Eugenio DAMACENO Hottz
RMRemy Martins-Gonçalves
Remy Martins-Gonçalves
LPLohanna Palhinha
Lohanna Palhinha
IAIsaclaudia G. Azevedo-Quintanilha
Isaclaudia G. Azevedo-Quintanilha
MCMariana M. de Campos
Mariana M. de Campos
PBPatricia Bozza
Patricia Bozza
Accumulating evidence into the pathogenesis of COVID-19 highlights a hypercoagulability state with high risk of life-threatening thromboembolic complications. However, the mechanisms of hypercoagulability and their link to hyperinflammation remain poorly understood. Here, we investigate functions and mechanisms of platelet activation and platelet-monocyte interactions in inflammatory amplification during SARS-CoV-2 infection. We used a combination of immunophenotyping, single-cell analysis, functional assays, and pharmacological approaches to gain insights on mechanisms. Critically ill patients with COVID-19 exhibited increased platelet-monocyte aggregates formation. We identified a subset of inflammatory monocytes presenting high CD16 and low HLA-DR expression as the subset mainly interacting with platelets during severe COVID-19. Single-cell RNA-sequencing analysis indicated enhanced fibrinogen receptor Mac-1 in monocytes from patients with severe COVID-19. Monocytes from patients with severe COVID-19 displayed increased platelet binding and hyperresponsiveness to P-selectin and fibrinogen with respect to tumor necrosis factor-α and interleukin-1β secretion. Platelets were able to orchestrate monocyte responses driving tissue factor (TF) expression, inflammatory activation, and inflammatory cytokines secretion in SARS-CoV-2 infection. Platelet-monocyte interactions ex vivo and in SARS-CoV-2 infection model in vitro reciprocally activated monocytes and platelets, inducing the heightened secretion of a wide panel of inflammatory mediators. We identified platelet adhesion as a primary signaling mechanism inducing mediator secretion and TF expression, whereas TF signaling played major roles in amplifying inflammation by inducing proinflammatory cytokines, especially tumor necrosis factor-α and interleukin-1β. Our data identify platelet-induced TF expression and activity at the crossroad of coagulation and inflammation in severe COVID-19.

30 December 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
LSLuciana Souza-Moreira
Luciana Souza-Moreira
Vinicius Cardoso SoaresVinicius Cardoso Soares
Vinicius Cardoso Soares
Suelen Silva Gomes DiasSuelen Silva Gomes Dias
Suelen Silva Gomes Dias
PBPatricia Bozza
Patricia Bozza
Mesenchymal stromal cells (MSCs) are a potential therapy for many chronic inflammatory diseases due to their regenerative, immunologic and anti-inflammatory properties. The two-way dialogue between MSCs and macrophages is crucial to tissue regeneration and repair. Previous research demonstrated that murine adipose-derived MSC conditioned medium (ASCcm) reprograms macrophages to an M2-like phenotype which protects from experimental colitis and sepsis. Here, our focus was to determine the molecular mechanism of lipid droplet biogenesis in macrophages re-educated using ASCcm. Adipose-derived MSC conditioned medium promotes phosphorylation of AKT/mTOR pathway proteins in macrophages. Furthermore, increased expression of PPARγ, lipid droplet biogenesis and PGE2 synthesis were observed in M2-like phenotype macrophages (high expression of arginase 1 and elevated IL-10). Treatment with mTOR inhibitor rapamycin or PPARγ inhibitor GW9662 suppressed lipid droplets and PGE2 secretion. However, these inhibitors had no effect on arginase-1 expression. Rapamycin, but not GW9662, inhibit IL-10 secretion. In conclusion, we demonstrate major effects of ASCcm to reprogram macrophage immunometabolism through mTOR and PPARγ dependent and independent pathways.